583 related articles for article (PubMed ID: 31434341)
1. A Stage-Based Approach to Therapy in Parkinson's Disease.
Carrarini C; Russo M; Dono F; Di Pietro M; Rispoli MG; Di Stefano V; Ferri L; Barbone F; Vitale M; Thomas A; Sensi SL; Onofrj M; Bonanni L
Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31434341
[TBL] [Abstract][Full Text] [Related]
2. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W; Schulz JB
J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.
Kalinderi K; Fidani L; Katsarou Z; Bostantjopoulou S
Int J Clin Pract; 2011 Dec; 65(12):1289-94. PubMed ID: 22093536
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatment of Parkinson disease: a review.
Connolly BS; Lang AE
JAMA; 2014 Apr 23-30; 311(16):1670-83. PubMed ID: 24756517
[TBL] [Abstract][Full Text] [Related]
5. Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.
Politi C; Ciccacci C; Novelli G; Borgiani P
Neuromolecular Med; 2018 Mar; 20(1):1-17. PubMed ID: 29305687
[TBL] [Abstract][Full Text] [Related]
6. The impact and management of nonmotor symptoms of Parkinson's disease.
Lyons KE; Pahwa R
Am J Manag Care; 2011 Oct; 17 Suppl 12():S308-14. PubMed ID: 22087551
[TBL] [Abstract][Full Text] [Related]
7. Rationale for current therapies in Parkinson's disease.
Romrell J; Fernandez HH; Okun MS
Expert Opin Pharmacother; 2003 Oct; 4(10):1747-61. PubMed ID: 14521485
[TBL] [Abstract][Full Text] [Related]
8. New pharmacological options for treating advanced Parkinson's disease.
Devos D; Moreau C; Dujardin K; Cabantchik I; Defebvre L; Bordet R
Clin Ther; 2013 Oct; 35(10):1640-52. PubMed ID: 24011636
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in the pharmacological treatment of Parkinson's disease.
Tuite P; Riss J
Expert Opin Investig Drugs; 2003 Aug; 12(8):1335-52. PubMed ID: 12882620
[TBL] [Abstract][Full Text] [Related]
10. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.
Faulkner MA
Expert Opin Drug Saf; 2014 Aug; 13(8):1055-69. PubMed ID: 24962891
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for Parkinson's disease.
Morgan JC; Sethi KD
Expert Opin Emerg Drugs; 2006 Sep; 11(3):403-17. PubMed ID: 16939381
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective approaches to halt Parkinson's disease progression.
Sola P; Krishnamurthy PT; Kumari M; Byran G; Gangadharappa HV; Garikapati KK
Neurochem Int; 2022 Sep; 158():105380. PubMed ID: 35718278
[TBL] [Abstract][Full Text] [Related]
13. Treatment of the motor and non-motor symptoms in Parkinson's disease according to cluster symptoms presentation.
Lauretani F; Saginario A; Ceda GP; Galuppo L; Ruffini L; Nardelli A; Maggio M
Curr Drug Targets; 2014; 15(10):943-7. PubMed ID: 25174438
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease: making the diagnosis, selecting drug therapies.
Scharre DW; Mahler ME
Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845
[TBL] [Abstract][Full Text] [Related]
15. New insight into the therapeutic role of the serotonergic system in Parkinson's disease.
Ohno Y; Shimizu S; Tokudome K; Kunisawa N; Sasa M
Prog Neurobiol; 2015 Nov; 134():104-21. PubMed ID: 26455457
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's Disease.
Reich SG; Savitt JM
Med Clin North Am; 2019 Mar; 103(2):337-350. PubMed ID: 30704685
[TBL] [Abstract][Full Text] [Related]
17. Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited.
Laurencin C; Danaila T; Broussolle E; Thobois S
Rev Neurol (Paris); 2016; 172(8-9):512-523. PubMed ID: 27476416
[TBL] [Abstract][Full Text] [Related]
18. Understanding Parkinson's disease: detection and early disease management.
Mackin LA
Lippincotts Prim Care Pract; 2000; 4(6):595-607. PubMed ID: 11933373
[TBL] [Abstract][Full Text] [Related]
19. Approaching disturbed sleep in late Parkinson's Disease: first step toward a proposal for a revised UPDRS.
Askenasy JJ
Parkinsonism Relat Disord; 2001 Oct; 8(2):123-31. PubMed ID: 11489677
[TBL] [Abstract][Full Text] [Related]
20. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
